Rheumatology (Feb 2021)

Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors

  • Ciro Manzo,
  • Marco Isetta

DOI
https://doi.org/10.5114/reum.2021.102600
Journal volume & issue
Vol. 59, no. 1
pp. 62 – 63

Abstract

Read online

Polymyalgia rheumatica (PMR) and PMR-like syndromes are among the most frequent rheumatologic immuno-related adverse events (IRAEs) induced by cancer immunotherapy with “checkpoint inhibitors” (ICIs). Our short communication addresses two key methodological issues laid bare by published literature : 1) how to diagnose PMR and PMR-like syndromes following ICI therapy, 2) how PMR/PMR-like syndromes following ICI therapy are described as adverse drug reactions (ADRs).

Keywords